Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect.
- Resource Type
- Article
- Authors
- Lugini, Luana; Federici, Cristina; Borghi, Martina; Azzarito, Tommaso; Marino, Maria Lucia; Cesolini, Albino; Spugnini, Enrico Pierluigi; Fais, Stefano
- Source
- Journal of Enzyme Inhibition & Medicinal Chemistry. Aug2016, Vol. 31 Issue 4, p538-545. 8p.
- Subject
- *PROTON pump inhibitors
*GENERIC drugs
*ANTINEOPLASTIC agents
*CANCER chemotherapy
*CANCER cells
*DRUG efficacy
*LANSOPRAZOLE
*THERAPEUTICS
*CANCER treatment
- Language
- ISSN
- 1475-6366
Context: Tumor acidity represents a major cause of chemoresistance. Proton pump inhibitors (PPIs) can neutralize tumor acidity, sensitizing cancer cells to chemotherapy. Objective: To compare the anti-tumor efficacy of different PPIsin vitroandin vivo. Materials and methods:In vitroexperiments PPIs anti-tumor efficacy in terms of cell proliferation and cell death/apoptosis/necrosis evaluation were performed.In vivoPPIs efficacy experiments were carried out using melanoma xenograft model in SCID mice. Results: Lansoprazole showed higher anti-tumor effect when compared to the other PPIs. The lansoprazole effect lasted even upon drug removal from the cell culture medium and it was independent from the lipophilicity of the PPIs formulation. Discussion: These PPIs have shown different anti-tumoral efficacy, and the most effective at low dose was lansoprazole. Conclusion: The possibility to contrast tumor acidity by off-label using PPIs opens a new field of oncology investigation. [ABSTRACT FROM AUTHOR]